

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	THOUSAND BRITAINS	ATTORNEY DOCKET NO.	CONFIRMATION NO.
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/734,625	12/15/2003	Geoffrey Allan	1633.0400002/SRL/NJL	2541
26111 STERNE, KES	7590 07/10/200 SSLER, GOLDSTEIN &	EXAM	EXAMINER	
1100 NEW YO	ORK AVENUE, N.W.	FAY, ZOHREH A		
WASHINGTO	ON, DC 20005		ART UNIT	PAPER NUMBER
			1612	
			MAIL DATE	DELIVERY MODE
			07/10/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Application No. Applicant(s) 10/734.625 ALLAN ET AL. Office Action Summary Examiner Art Unit ZOHREH A. FAY 1612 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

earned patent term adjustment.	See 37 CFR 1.704(b).		

Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.736(a). In ore ovent, however, may a reply be timely filled.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (5) MONTHS from the mindle date of this communication.  - Failure to reply whith the set or standard period for reply will by tasted parts or standard period for reply will by the set. Set or standard period for reply will be tasted. cause the application to become ARAMONED (38 U.S.C, § 133).  Any reply received by the Office later than three months after the making date of this communication, even if timely filled, may reduce any earned paint term adjustment. See 37 CFR 1.740(b).				
Status				
1) Responsive to communication(s) filed on <u>08 April 2008</u> .				
2a)☑ This action is FINAL. 2b)☐ This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims				
4) Claim(s) 1-17 is/are pending in the application.				
4a) Of the above claim(s) 6.7 and 10-13 is/are withdrawn from consideration.				
5) Claim(s) is/are allowed.				
6) Claim(s) 1-5, 8, 9 and 14-17 is/are rejected.				
7) Claim(s) is/are objected to.				
8) Claim(s) are subject to restriction and/or election requirement.				
Application Papers				
9) The specification is objected to by the Examiner.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).				
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119				
40) 4 1 2 2 4 4 2 4 4 4 4 4 4 4 4 4 4 4 4 4				
12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☐ All b) ☐ Some * c) ☐ None of:				
a) ☐ All b) ☐ Some * c) ☐ None of:  1. ☐ Certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in Application No				
a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage				
a ☐ All b ☐ Some * c ☐ None of:  1. ☐ Certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in Application No  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).				
a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage				
a ☐ All b ☐ Some * c ☐ None of:  1. ☐ Certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in Application No  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).				
a ☐ All b ☐ Some * c ☐ None of:  1. ☐ Certified copies of the priority documents have been received.  2. ☐ Certified copies of the priority documents have been received in Application No  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).				

Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/95/00) Paper Not/SMall Date	4) Interview Summary (PTO-413) Paper Nots/Mail Date. 5.) Neitice of Informal Pater Lity Fliration 6) Other:	

Application/Control Number: 10/734,625

Art Unit: 1612

Claims 1-17 are pending in the instant application.

Claims 1-5, 8, 9 and 14-17 are presented for examination.

The remarks filed on April 8, 2008 have been received and entered.

Claims 1-5, 8, 9 and 14-17 are rejected under 35 U.S.C. 103 (a) as being unpatentable over Gwori et al. (AJH 1992) and Gowri et al. (Am J physiol Endocrinol Metab, 2000) in view of Copp et al. (US 4,572,913) for the reasons set forth on pages 2-3 of the office action of January 1, 2008.

Applicant's arguments and remarks have been carefully considered, but are not deemed to be persuasive. Applicant in his remarks argues that the examiner has made the improper determination of masoprocol's status as a lipoxygenase inhibitor. However, applicant fails to establish that such compound does not have lipoxygenase inhibitory activity and the lowering of the serum triglycerides and hypertension is not as a result of the inhibitory activity of the compound on lipoxygenase pathway. Applicant's arguments that the references do not teach the effect of masoprocol on the 5-lipoxygense have been noted. The arguments are not well taken, considering that the prior art teaches the effect of masprocol on lipoxygenase pathway in general, which can cover 5, 12 or any other lipoxygenase pathways. Therefore, in view of the prior art and based on KSR a person skilled in the art would have been motivated to try and use a compound having lipoxygenase activity inhibitory activity for the treatment of elevated serum triglycerides or hypertension.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 10/734,625

Art Unit: 1612

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ZOHREH A. FAY whose telephone number is (571)272-0573. The examiner can normally be reached on Monday to Friday 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Fredrick Krass can be reached on (571) 272-0580. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit: 1612

ZF /Zohreh A Fay/ Primary Examiner, Art Unit 1612